We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Study of Soy Isoflavones in Asthma (SOYA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01052116
Recruitment Status : Completed
First Posted : January 20, 2010
Results First Posted : January 14, 2016
Last Update Posted : January 14, 2016
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Robert A. Wise, M.D., American Lung Association Asthma Clinical Research Centers

Brief Summary:
The trial is designed to study the effects of soy supplements on asthma control.

Condition or disease Intervention/treatment Phase
Asthma Drug: Soy isoflavone supplement Drug: Placebo Phase 4

Detailed Description:
Asthma is a common disease that has a major impact on morbidity and health care costs. Although the prevalence and severity of asthma have increased over the last several decades, the specific causes remain unknown. One possible mechanism is a change in diet. Yet, epidemiological and interventional studies designed to identify a key nutrient or antioxidant vitamin that may be responsible for the increase in disease severity have produced inconsistent results. A recent pilot study showed a soy isoflavone supplement reduces exhaled nitric oxide (FeNO) and ex vivo LTC4 synthesis in patients with inadequately controlled asthma. This clinical trial is designed to test the novel hypothesis that dietary supplementation with soy isoflavones is an effective treatment in patients with poorly controlled asthma. The study will include 380 patients with low dietary soy intake, 12 years of age or older, who are taking either inhaled corticosteroids or leukotriene modifiers and have inadequately controlled asthma. Participants will be randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein and glycitein; 100 mg daily of the glycoside forms) or placebo for six months. The results of this trial will increase understanding of the role of diet in asthma; could identify a novel, safe and relatively inexpensive treatment for patients with asthma; and potentially will have a substantial impact on public health in the United States.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 386 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Study of Soy Isoflavones in Asthma
Study Start Date : March 2010
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Soy Isoflavone
Oral isoflavone supplement (100 mg/day)
Drug: Soy isoflavone supplement
Oral soy isoflavone supplement (100 mg/day)
Other Name: Soy supplement

Placebo Comparator: Placebo
Matching placebo
Drug: Placebo

Primary Outcome Measures :
  1. Mean Change From Baseline to 24 Weeks for FEV1 [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 12 or older
  • Physician diagnosed asthma

    • FEV1 equal or greater than 50% predicted pre-bronchodilator
    • At least 12% increase in FEV1 15-3 minutes after inhaling 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 8 mg/mL). Either of these can be available from the previous 2 years
    • Currently prescribed daily controller asthma medication
  • Poor asthma control (at least one of the following)

    • A score of 1.5 or greater on the Juniper Asthma Control Questionnaire
    • Use of beta-agonist for asthma symptoms two or more times per week
    • Nocturnal awakening with asthma symptoms more than once per week
    • Two or more episodes of asthma symptoms in the past 12 months with each requiring at least one of the following: emergency department visit, unscheduled physician visit, prednisone course, hospitalization
  • Smoking status

    • Non-smoker for 6 months or longer
    • Less than 10 pack-years smoking history

Exclusion Criteria:

  • Pulmonary function

    • FEV1 less than 50% predicted pre-bronchodilator
  • Other major chronic illnesses

    • Conditions which in the judgment of the study physician would interfere with participation in the study, e.g., non-skin cancer, endocrine disease, coronary artery disease, severe hypertension, immunodeficiency states
    • History of thyroid disease, breast cancer, ovarian, or endometrial cancer
    • History of physician diagnosis of chronic bronchitis, emphysema, or COPD
  • Medication use

    • Current consumption of soy isoflavone supplements
    • Oral corticosteroid use within the past 6 weeks
    • Use of tamoxifen
  • Use of an investigational treatment in the previous 30 days
  • "Drug" allergy

    • Known adverse reaction to genistein, other phytoestrogens, or soy products
  • Females of childbearing potential

    • Pregnant or lactating. Participants must agree to use effective contraception during the trial.
  • Non-adherence

    • Inability or unwillingness to provide consent or, in the case of children, inability or unwillingness of the child to provide assent
    • Inability to swallow study medication
    • Inability to perform baseline measurements
    • Completion of less than 10 of the last 14 days diary entries during screening period
    • Inability to be contacted by telephone
    • Intention to move out of the area within 6 months
  • Other

    • Recent asthma exacerbation (within 6 weeks)
    • Recent upper respiratory infection (within 2 weeks)
    • Body weight less than 77 pounds (35 kg)
    • Intake of soy or soy-enriched foods 1 or more times a week
    • Change in diet over the past month or expected change in diet during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01052116

Show Show 18 study locations
Sponsors and Collaborators
American Lung Association Asthma Clinical Research Centers
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Lewis J Smith, MD Northwestern University
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Robert A. Wise, M.D., Director of Data Coordinating Center, American Lung Association Asthma Clinical Research Centers
ClinicalTrials.gov Identifier: NCT01052116    
Other Study ID Numbers: ALAACRC-10
R01HL087987-01A2 ( Other Identifier: NIH/NHLBI )
R01 HL0088367-01A2 ( Other Identifier: NIH/NHLBI )
First Posted: January 20, 2010    Key Record Dates
Results First Posted: January 14, 2016
Last Update Posted: January 14, 2016
Last Verified: December 2015
Keywords provided by Robert A. Wise, M.D., American Lung Association Asthma Clinical Research Centers:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases